CD274 and head and neck squamous cell carcinoma: Programmed death ligand 1 (PD-L1) positive advanced and metastatic HNSCC patients are likely to be sensitive to immunotherapy, immune checkpoints such as programmed death 1 (PD-1) treatment have received widespread attention, and related inhibitory antibodies can improve the prognosis of patients with HNSCC [8].